Eleonora Zaccarelli

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · Journal of Clinical Oncology · 2018 · 74 citations

Medicine, Oncology, Pharmacotherapy +13

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Sandro Pignata, Vittoria Carbone, Eleonora Zaccarelli et al. · The Lancet Oncology · 2023 · 51 citations

Medicine, Oncology, Pharmacology +11

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia et al. · International Journal of Gynecological Cancer · 2021 · 36 citations

Medicine, Gynecology, Oncology +17

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer

Nicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni et al. · British Journal of Cancer · 2019 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +17